摘要
Objective: To investigate the value of mid-pregnancy Down syndrome risk screening in predicting adverse maternal and fetal outcomes. Methods: 536 mothers who underwent mid-pregnancy screening for Down syndrome at Chengyang District Maternal and Child Healthcare and Family Planning Service Center from January 2021 to December 2022 were selected for retrospective analysis. The risk was calculated using the Asian population database in the American prenatal screening software PRISCA 4.0, combined with the age, gestational week, and body mass of the day of the pregnant women's blood collection. Results: The screening results showed that there were 469, 54, and 13 cases in the low-risk, critical-risk, and high-risk groups, respectively, and there were no statistically significant differences in the age and body mass of each group (P > 0.05). However, there was a significant difference between the adverse fetal outcomes in low-risk, critical-risk, and high-risk groups (P < 0.05); and the screening results showed that there was a significant difference between the adverse maternal outcomes in the low-risk, critical-risk, and high-risk groups (P < 0.05). Conclusion: There is a relationship between the high risk of Down syndrome detected through screening and adverse maternal and fetal outcomes. Besides, the false positive and negative rates of Down syndrome screening results are positively correlated with adverse maternal and fetal outcomes.
参考
Feng J, Cao S, Jiu F, et al., 2021, The Value of Mid-Pregnancy Down Syndrome Screening Risk in Predicting Adverse Maternal and Fetal Pregnancy Outcomes. China Maternal and Child Health Care, 36(6): 1391–1394.
Wang Z, Xu J, Liang Y, et al., 2022, Association of Mid-Pregnancy Serum Down Syndrome Screening with Adverse Pregnancy Outcomes. Basic Medicine and Clinics, 42(6): 955–959.
Qi H, 2021, Analysis of Mid-Pregnancy Prenatal Screening and Prenatal Diagnosis of Down Syndrome. China Maternal and Child Health Care, 36(24): 5796–5799.
Li D, Chen J, Huang X, et al., 2015, Retrospective Analysis of Mid-Pregnancy Low-Risk Down’s Syndrome Screening Population. Chinese Journal of Eugenics and Genetics, 23(5): 42–43.
Gao H, An Y, Gao H, 2014, Clinical Analysis of Prenatal Screening Results of 7076 Cases of Down Syndrome in Mid-Pregnancy. Marker Immunoanalytical and Clinical, 21(3): 255–257.
Zhang J, 2017, Analysis of the Value of Mid-Pregnancy Serologic Screening for Down Syndrome in Predicting Adverse Pregnancy Outcomes. China Maternal and Child Health, 32(24): 6219–6222.
Han L, 2020, Relationship Between High Risk of Mid-Pregnancy Down Syndrome Serologic Screening and Adverse Pregnancy Outcomes. Henan Medical Research, 29(31): 5810–5812.
Zhang P, Wang J, Meng Y, 2014, Clinical Significance of Mid-Pregnancy Serum and Ultrasound Screening for Down Syndrome. Journal of Clinical Pediatrics, 2014(5): 434–437.
Ji J, 2023, Relationship Between High Risk of Mid-Pregnancy Serologic Screening for Down Syndrome and Adverse Pregnancy Outcomes. Mother and Child World, 2023(14): 28–30.
Zhu Y, Kan C, Xiao Y, et al., 2020, Reference Value of Mid-Pregnancy Quadruple Screening for Down Syndrome. Hebei medicine, 26(4): 615–619.
Chen Z, Du Z, Wang D, 2020, Clinical Value of Mid-Pregnancy NIPT Combined with Serum AFP, free?-hCG and uE3 Testing in Screening for Down Syndrome. Chinese Clinical Journal of Obstetrics and Gynecology, 21(1): 79–80.
Li Q, He F, 2022, Analysis of the Value of Mid-Pregnancy Down Syndrome Screening in Elderly Pregnant Women. Frontiers of Medicine, 12(3): 48–50.